Saratoga Investment Corp 7.50%
Moat Score — Saratoga Investment Corp 7.50%
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Savara holds patents on the molgramostim drug-device combination running through 2043 (and a liquid formulation patent expected to protect Europe through 2041), and MOLBREEVI would be the first approved inhaled therapy for autoimmune PAP if cleared, but the IP is tied to a single asset rather than a broad platform. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Savara's fully outsourced clinical and manufacturing model keeps overhead low, but this is a lean operating structure rather than a true unit-cost advantage over any future competitor, since it owns no proprietary manufacturing capability. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | If approved, MOLBREEVI would be the only medicine for a rare disease with no approved alternative and an invasive standard of care (whole lung lavage), which would support real pricing power typical of orphan-drug launches, though this power does not exist yet absent approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A single inhaled therapy for a rare respiratory disease generates no network effects; value does not compound with additional users in any platform sense. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once physicians and patients adopt a non-invasive inhaled therapy over whole lung lavage, meaningful behavioral switching costs could develop, but today there is no commercial product and therefore no established patient base to retain. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Autoimmune PAP is a genuinely rare disease with a small patient population, which limits the commercial incentive for a second company to develop a competing inhaled GM-CSF therapy once Savara secures approval and orphan exclusivity. |